Table 1:
Demographic and clinical characteristics of childhood cancer survivors in discovery and replication cohorts, split by sex
| Characteristic | Discovery cohort (CCSS) | Replication cohort (SJLIFE) | ||||
|---|---|---|---|---|---|---|
| Sex-combined (N=2,453) | Female (N=1,289) | Male (N=1,164) | Sex-combined (N=1,417) | Female (N=646) | Male (N=771) | |
| % (N) or median (IQR) | % (N) or median (IQR) | % (N) or median (IQR) | % (N) or median (IQR) | % (N) or median (IQR) | % (N) or median (IQR) | |
| Sex | ||||||
| Female | 52.5% (1,289) | 45.6% (646) | ||||
| Male | 47.5% (1,164) | 54.4% (771) | ||||
| Attained age (years) | 42 (36–48) | 42 (36–48) | 43 (37–48) | 31 (26–39) | 31 (26–39) | 32 (26–38) |
| Attained height (cm) | 168 (163–178) | 163 (157–168) | 178 (170–183) | 169 (162–177) | 162 (157–167) | 176 (170–181) |
| Attained weight (kg) | 77 (64–91) | 68 (59–82) | 84 (75–96) | 79 (65–95) | 70 (60–86) | 86 (73–100) |
| Age at cancer diagnosis (years) | 5 (2–12) | 5 (2–12) | 6 (3–12) | 6 (3–12) | 6 (3–13) | 7 (3–12) |
| Primary cancer diagnosis | ||||||
| Leukemia | 35.6% (874) | 38.9% (501) | 32.0% (373) | 35.1% (497) | 35.6% (230) | 34.6% (267) |
| Hodgkin lymphoma | 15.0% (367) | 15.9% (205) | 13.9% (162) | 12.5% (177) | 13.3% (86) | 11.8% (91) |
| Kidney tumors | 12.6% (309) | 14.7% (190) | 10.2% (119) | 7.3% (104) | 9.6% (62) | 5.4% (42) |
| Soft tissue sarcoma | 9.7% (237) | 9.0% (116) | 10.4% (121) | 7.5% (106) | 7.1% (46) | 7.8% (60) |
| Central nervous system tumors | 9.2% (226) | 5.7% (74) | 13.1% (152) | 14.3% (203) | 12.4% (80) | 16.0% (123) |
| Neuroblastoma | 9.1% (224) | 10.9% (141) | 7.1% (83) | 4.7% (66) | 4.8% (31) | 4.5% (35) |
| Non-Hodgkin lymphoma | 8.8% (216) | 4.8% (62) | 13.2% (154) | 7.5% (106) | 5.4% (35) | 9.2% (71) |
| Other | -- | -- | -- | 11.2% (158) | 11.8% (76) | 10.6% (82) |
| Chemotherapy receipt (any) | ||||||
| IV methotrexate | 18.5% (454) | 18.1% (233) | 19.0% (221) | 29.2% (414) | 28.2% (182) | 30.1% (232) |
| IT methotrexate | 38.4% (941) | 37.9% (488) | 38.9% (453) | 38.3% (543) | 37.6% (243) | 38.9% (300) |
| Glucocorticoids | 47.2% (1,158) | 47.0% (606) | 47.4% (552) | 48.3% (685) | 46.9% (303) | 49.5% (382) |
| Methotrexate dosea (in mg/m2) | ||||||
| IV methotrexate | 3,051 (805 – 6,058) | 3,120 (596 – 6,550) | 2,951 (923 – 5,510) | 1,567 (211 – 2,952) | 1,681 (370 – 2,922) | 1,515 (185 – 3,153) |
| IT methotrexate | 126 (71 – 222) | 132 (72 – 223) | 120 (68–222) | 158 (93 – 233) | 171 (84 – 235) | 150 (96 – 233) |
| Radiation therapy receiptb (any) | ||||||
| Any site | 63.0% (1,545) | 61.0% (786) | 65.2% (759) | 48.2% (683) | 48.9% (316) | 47.6% (367) |
| Radiation to head regionc | 45.9% (1,125) | 43.2% (557) | 48.8% (568) | 38.5% (545) | 37.3% (241) | 39.4% (304) |
| Radiation to trunk regiond | 37.0%% (908) | 37.4% (482) | 36.6% (426) | 25.7% (364) | 26.6% (172) | 24.9% (192) |
| Radiation to limb regionse | 1.4% (34) | 1.7% (22) | 1.0% (12) | 3.7% (52) | 4.3% (28) | 3.1% (24) |
| Radiation therapy dosef (in cGy) | ||||||
| Any site | 2,400 (2,000 – 3,900) | 2,400 (1,800 – 3,600) | 2,500 (2,000 – 4,100) | 2,600 (2,100 – 4,500) | 2,600 (2,100 – 4,000) | 2,600 (2,100 – 5,070) |
| Head regions | 2,400 (1,800 – 3,800) | 2,400 (1,800 – 3,500) | 2,400 (2,000 – 4,200) | 2,600 (2,100 – 4,500) | 2,600 (2,100 – 3,700) | 2,600 (2,100 – 5,300) |
| Trunk regions | 3,000 (2,000 – 3,900) | 2,900 (2,000 – 4,000) | 3,000 (2,000 – 3,800) | 2,600 (2,100 – 3,500) | 2,600 (2,175 – 3,600) | 2,600 (2,100 – 3,500) |
| Limb regions | 4,750 (3,625 – 5,900) | 4,700 (3,000 – 5,850) | 4,750 (4,275 – 5,725) | 2,650 (2,000 – 4,600) | 2,700 (2,000 – 4,522) | 2,650 (2,000 – 3,500) |
a.
Dose distributions only include survivors who received any IV or IT methotrexate.
b.
Received more than high scatter doses of radiation therapy.
c.
Head region refers to the brain, neck, or other head region.
d.
Trunk region refers to the chest, abdomen, or pelvis region.
e
Limb regions refer to arm or leg regions.
f.
Maximum cumulative dosimetry dose; dose distributions only include survivors who received >high scatter doses.
Abbreviations: IQR, inter-quartile range; cm, centimeters; kg, kilograms; IV, intravenous; IT, intrathecal; cGy, centigray.